Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Charles River Laboratories International, Inc.

NYSE: CRL · Industrial Applications and Services · 7 alerts · CIK 1100682

Share price
$335.52Close, Nov 16
Market cap
$16.1B
Shares outstanding
47.92MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Commercial Physical & Biological ResearchSIC 8731

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Charles River Laboratories International, Inc. filings on SEC EDGAR ↗

6:14 AM ET 8-K
M&A Deal

Charles River Laboratories International Signs $470M M&A Deal with Frontage Holdings Corporation

Charles River Laboratories has entered into definitive agreements to acquire Frontage Holdings Corporation’s bioanalysis and DMPK operations in Exton, Pennsylvania for $470 million in cash. The deal includes up to $75 million in additional contingent payments and is intended to expand Charles River's clinical bioanalysis capabilities to support clients across the full drug development lifecycle. The transaction is expected to close in the first half of 2027.

Value
$470M
Counterparty
Frontage Holdings Corporation
9:08 AM ET 10-Q
Financial Results

Charles River Laboratories International Q3 2026 Results: Net Income $333M, Up 512.0% YoY

For the three months ended September 26, 2026, Charles River Laboratories reported total revenue of $982.7 million, a slight decrease from $1.00 billion in the prior year. Despite the revenue dip, net income attributable to common shareholders rose significantly to $333.1 million, primarily driven by a substantial income tax benefit of $163.8 million.

Key figure
Net income $333M · +512.0% YoY
7:05 AM ET 8-K
Financial Results

Charles River Laboratories International Financial Results

Charles River Laboratories reported Q3 2026 revenue of $982.7 million and organic revenue growth of 4.7%, marking its second consecutive quarter of organic growth. The company increased its full-year 2026 guidance for both revenue and non-GAAP earnings per share, driven by outperformance in its Discovery and Safety Assessment (DSA) segment.

Term
Q3 2026

“Our third-quarter results were highlighted by a return to organic revenue growth for the second consecutive quarter and significant margin expansion, which drove non-GAAP earnings per share growth of 27%. We were pleased with the performance of our DSA and Manufacturing segments, which both delivered organic revenue growth and improved profitability.”

James C. Foster, Chairman, President and Chief Executive Officer
4:51 PM ET Form 4
Insider Selling

Charles River Laboratories International Insider James C. Foster Sells $8.41M of Stock

James C. Foster sold 24,042 shares of Charles River Laboratories International, Inc. at $350.00 a share, worth $8.41M in total on Oct 22, 2026. Shares held after the trade: 31,596 (-43.2%).

Value
$8.41M
Shares
24,042
Price
$350.00
Holding change
-43.2%
Trade date
Oct 22, 2026
6:46 PM ET Form 4
Insider Selling

Charles River Laboratories International CEVP, Disc & Safety Assessment Shannon M. Parisotto Sells $743K of Stock

Shannon M. Parisotto, CEVP, Disc & Safety Assessment, sold 2,156 shares of Charles River Laboratories International, Inc. at $344.41 a share, worth $743K in total on Oct 21, 2026. Shares held after the trade: 4,807 (-31.0%).

Value
$743K
Shares
2,156
Price
$344.41
Role
CEVP, Disc & Safety Assessment
Holding change
-31.0%
Trade date
Oct 21, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.